Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1Genitourinary 1Gastrointestinal 1Dermatologic 1CNS 1Breast 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leukemia 1Hematologic Neoplasms 1

Interventions

venetoclax 136Cytarabine 106Cyclophosphamide 104Specimen Handling 94fludarabine 86Azacitidine 84Biopsy 71Rituximab 45Methotrexate 42Daunorubicin 41fludarabine phosphate 40Vincristine 35Magnetic Resonance Spectroscopy 35Dexamethasone 35blinatumomab 31Injections 31Decitabine 31Granulocyte Colony-Stimulating Factor 29Mycophenolic Acid 28Whole-Body Irradiation 27Idarubicin 27ibrutinib 26Tacrolimus 26Prednisone 26Etoposide 26Busulfan 25Melphalan 24Doxorubicin 24acalabrutinib 23Calcium Dobesilate 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Midazolam × Other hematologic neoplasm × 90 days × Clear all
NCT04067336 2026-05-13

First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1/2 Active not recruiting
263 enrolled 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡